Cargando…
Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design
INTRODUCTION: Therapeutic advances have markedly increased life expectancy for those with cystic fibrosis (CF), resulting in a median predicted survival over 50 years. Consequently, people with CF (pwCF) are living through their reproductive years and the rate of pregnancy is rapidly rising. Despite...
Autores principales: | Jain, Raksha, Magaret, Amalia, Vu, Phuong T, VanDalfsen, Jill M, Keller, Ashley, Wilson, Alexandra, Putman, Melissa S, Mayer-Hamblett, Nicole, Esther, Charles R, Taylor-Cousar, Jennifer L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204448/ https://www.ncbi.nlm.nih.gov/pubmed/35710144 http://dx.doi.org/10.1136/bmjresp-2022-001289 |
Ejemplares similares
-
Burden of cystic fibrosis in children <12 years of age prior to the introduction of CFTR modulator therapies
por: Bresnick, Kathryn, et al.
Publicado: (2021) -
Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor
por: Bessonova, Leona, et al.
Publicado: (2018) -
Adherence to cystic fibrosis transmembrane conductance regulator (CFTR) modulators: analysis of a national specialty pharmacy database
por: Mehta, Zumi, et al.
Publicado: (2021) -
Intestinal current measurement and nasal potential difference to make a diagnosis of cases with inconclusive CFTR genetics and sweat test
por: Minso, Rebecca, et al.
Publicado: (2020) -
Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomised trials
por: Keogh, Ruth H, et al.
Publicado: (2022)